Premium
Engineered Heart Repair
Author(s) -
Fujita B,
Zimmermann WH
Publication year - 2017
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.724
Subject(s) - heart failure , medicine , myocyte , mammalian heart , cardiology , stem cell , microbiology and biotechnology , biology
There is a pressing need for the development of advanced heart failure therapeutics. Current state‐of‐the‐art is protection from neurohumoral overstimulation, which fails to address the underlying cause of heart failure, namely loss of cardiomyocytes. Implantation of stem cell‐derived cardiomyocytes via tissue‐engineered myocardium is being advanced to realize the remuscularization of the failing heart. Here, we discuss pharmacological challenges pertaining to the clinical translation of tissue‐engineered heart repair with a focus on engineered heart muscle (EHM).